Jie Deng, MD, PhD

Jie Deng, MD, PhD

Assistant Professor, Department of Radiation Oncology





Tumor Immunology, University of California, Los Angeles, CA


Resurrection Medical Center, Chicago, IL, 2019


MD, Geisel School of Medicine at Dartmouth, Hanover, NH, 2018
PhD, Geisel School of Medicine at Dartmouth, Hanover, NH, 2016
BS, University of Florida, Gainesville, FL, 2009


Radiation Oncology, University of California, Los Angeles, CA

Scientific Interests

Dr. Jie Deng is a physician-scientist who specializes in the study of myeloid cell biology in the context of cancer progression, radiation therapy and immunotherapy. Across numerous malignancies, myeloid cells (rather than lymphocytes) emerge as the predominant cellular subset within the tumor. Myeloid cells exhibit multifaceted roles but within the tumor, often converge towards immunosuppressive functions that enable tumor growth, metastasis, and resistance to therapy. Dr. Deng’s research program seeks to understand how these myeloid cells can be advantageously rewired away from immunosuppressive functions and towards the initiation of endogenous, durable anti-tumor immunity. 

Highlighted Publications

Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, Bolla M, Maingon P, de Reijke T, Joseph D, Ong WL, Sydes MR, Dearnaley DP, Tree AC, Carrier N, Nabid A, Souhami L, Incrocci L, Heemsbergen WD, Pos FJ, Zapatero A, Guerrero A, Alvarez A, San Segundo CG, Maldonado X, Reiter RE, Rettig MB, Nickols NG, Steinberg ML, Valle LF, Ma TM, Farrell MJ, Neilsen BK, Juarez JE, Deng J, Vangala S, Avril N, Jia AY, Zaorsky NG, Sun Y, Spratt D, Kishan AU. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate. J Clin Oncol. 2023 Aug 28;:JCO2300617. doi: 10.1200/JCO.23.00617. [Epub ahead of print] PubMed PMID: 37639648.

Sonni I, Dal Pra A, O'Connell DP, Ells Z, Benz M, Nguyen K, Yoon SM, Deng J, Smith C, Grogan T, Nickols NG, Cao M, Kishan AU, Calais J. (68)Ga-PSMA PET/CT-Based Atlas for Prostate Bed Recurrence After Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023 Jun;64(6):902-909. doi: 10.2967/jnumed.122.265025. Epub 2023 Feb 9. PubMed PMID: 36759200; PubMed Central PMCID: PMC10241009.

Schaafsma E, Croteau W, ElTanbouly M, Nowak EC, Smits NC, Deng J, Sarde A, Webber CA, Rabadi D, Cheng C, Noelle R, Lines JL. VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance. Cancer Immunol Res. 2023 Jan 3;11(1):38-55. doi: 10.1158/2326-6066.CIR-22-0116. PubMed PMID: 36260656; PubMed Central PMCID: PMC10544831.

Savjani RR, Lauria M, Bose S, Deng J, Yuan Y, Andrearczyk V. Automated Tumor Segmentation in Radiotherapy. Semin Radiat Oncol. 2022 Oct;32(4):319-329. doi: 10.1016/j.semradonc.2022.06.002. Review. PubMed PMID: 36202435.

Ma TM, Gafita A, Shabsovich D, Juarez J, Grogan TR, Thin P, Armstrong W, Sonni I, Nguyen K, Lok V, Reiter RE, Rettig MB, Steinberg ML, Kupelian PA, Yang DD, Muralidhar V, Chu C, Feng F, Savjani R, Deng J, Parikh NR, Nickols NG, Elashoff D, Czernin J, Calais J, Kishan AU. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with Highrisk Prostate Cancer and Negative Conventional Imaging. Eur Urol Oncol. 2022 Feb;5(1):100- 103. doi: 10.1016/j.euo.2021.01.006. Epub 2021 Feb 16. PubMed PMID: 33602654; PubMed Central PMCID: PMC10262977.